Understanding Neonatal Abstinence Syndrome
Neonatal abstinence syndrome represents a constellation of withdrawal symptoms triggered by abrupt cessation of in-utero drug exposure. Unlike voluntary substance use in adults, the affected infant never chose drug exposure yet experiences the full neurobiological consequences of dependency. The condition manifests across multiple physiological systems: hyperirritability, tremors, feeding difficulties, respiratory changes, and temperature dysregulation are hallmark signs.
Incidence rates have risen substantially in recent years across all socioeconomic and ethnic groups in the United States. Recognition and standardized assessment are critical because untreated or inadequately managed NAS can lead to:
- Seizures and severe neurological complications
- Dehydration and metabolic disturbance
- Developmental delays and learning difficulties later in childhood
- Behavioral and cognitive challenges during school years
The Finnegan score provides a validated, systematic method to measure symptom severity and guide intervention strategy.
Finnegan Score Calculation
The Finnegan score aggregates 21 individual symptom assessments across three physiological categories. Each symptom is assigned points based on severity and presence. The total score determines immediate management and monitoring frequency.
Total Finnegan Score = Cry + Sleep + Moro Reflex + Tremors + Muscle Tone
+ Excoriation + Myoclonic Jerks + Seizures + Body Temperature + Respiratory Rate
+ Sweating + Yawning + Mottling + Nasal Stuffiness + Sneezing + Nasal Flaring
+ Sucking Reflex + Feeding Tolerance + Regurgitation + Vomiting + Stool Pattern
Cry— Scored 0–3 points based on normal vs. high-pitched or continuous crying durationSleep— Scored 0–3 points reflecting hours of sleep after feedingMoro Reflex— Scored 0–3 points evaluating startle reflex intensityTremors— Scored 0–2 points based on absence, mild disturbance, or moderate-to-severe tremorsMuscle Tone— Scored 0–2 points for normal vs. increased muscle tensionTemperature— Scored 0–1 point if elevated above 38.2°C (100.8°F)Respiratory Rate— Scored 0–2 points if elevated above 60 breaths/min without lung diseaseGastrointestinal Symptoms— Individual points for feeding difficulty, regurgitation, vomiting, and abnormal stools
Timing and Protocol for Assessments
Proper Finnegan scoring requires adherence to specific timing and procedural guidelines:
- Initial assessment: Perform within the first 2 hours of life. This baseline establishes severity and informs immediate management decisions.
- Standard interval: Continue scoring every 4 hours while the score remains ≤7 points.
- Intensive monitoring: When any score reaches 8 or higher, switch to 2-hour intervals for at least 24 consecutive hours.
- Return to standard interval: Once scores drop to ≤7 for a full 24-hour period during intensive monitoring, revert to 4-hour intervals.
The infant must be awake and calm during assessment. If the baby is agitated or crying, soothe them first to obtain accurate behavioral observations. Document the assessment as reflecting the infant's behavior since the previous scoring session, not just the moment of evaluation.
Clinical Management Based on Finnegan Scores
Management thresholds guide clinicians on whether supportive care alone is sufficient or pharmacological treatment is warranted:
- Scores < 8: Non-pharmacological interventions are typically adequate. Continue frequent monitoring and supportive measures.
- Scores ≥ 8 in three consecutive assessments: Consider initiating pharmacotherapy alongside supportive care.
- Scores ≥ 12 in two consecutive assessments: Pharmacological intervention is strongly indicated.
- Severe symptoms: Seizures, significant dehydration, or respiratory compromise warrant immediate pharmacological treatment regardless of raw score.
Non-pharmacological strategies form the foundation of all NAS management and include demand feeding with high-calorie formulas, gentle handling and swaddling, dim lighting, minimal noise stimulation, and active parental involvement. Morphine is the most frequently used pharmacological agent, though methadone, phenobarbital, and clonidine are also employed depending on clinical context and institutional protocols.
Key Considerations in Finnegan Scoring
Accurate and consistent Finnegan scoring requires attention to several practical pitfalls and clinical nuances.
- Infant State Affects Symptom Severity — Crying, hunger, or overstimulation artificially elevate tremor and cry scores. Always soothe the infant before formal assessment. A calm, quiet environment produces reproducible, clinically meaningful scores that better reflect true withdrawal rather than acute distress.
- Timing Matters for Reproducibility — Scores performed at inconsistent intervals or by different providers using variable interpretation thresholds reduce reliability. Establish a standardized schedule, train all staff on point assignment criteria, and document the exact time of each assessment. This ensures trends are detectable and decisions aren't based on random variation.
- Drug Metabolism Varies Widely — The type, quantity, and timing of maternal drug use, combined with neonatal metabolism, genetics, and hydration status, influence symptom onset and duration. Opioids may manifest symptoms within 6–12 hours, while methadone or sedatives may delay onset to 48–72 hours. Anticipate delayed presentations in methadone-exposed infants.
- Long-Term Outcomes Remain Incompletely Understood — While acute NAS is well-characterized, the long-term neurodevelopmental, behavioral, and learning consequences are still being studied. Ensure families understand that early, aggressive management improves immediate outcomes, but ongoing developmental monitoring and early intervention services are recommended throughout infancy and early childhood.